ÂÜÀòÂÒÂ×

Christopher Cheng is Executive Director, RNA Technology & Manufacturing at Verve Therapeutics, where he leads the company’s mRNA design and manufacturing efforts with a focus on developing RNA-based gene editing medicines. Dr. Cheng brings extensive cross-functional experience to Verve in the fields of nucleic acid therapeutics, RNA biochemistry/biophysics, process development, drug delivery, and RNA/LNP manufacturing. Prior to joining Verve, Dr. Cheng was director, mRNA manufacturing and delivery at Casebia Therapeutics, where he established the in vivo gene editing technology platform for CRISPR-Cas9 and other CRISPR-based nucleases targeted to the liver. Prior to Casebia, Dr. Cheng led the nucleic acid technology group at Alexion Pharmaceuticals, where he focused on formulation and process development of mRNA therapeutic drug candidates for rare disease. Dr. Cheng completed his Ph.D. and postdoctoral training at Yale University. Dr. Cheng has co-authored over 25 peer-reviewed manuscripts.